Entering the era of medical AI, AIDOT, an AI medical device company, has once again pushed boundaries. AI, which is now taking over the medical market as it dominates the world, is projected to expand the global medical AI market from about 8.9 trillion KRW in 2021 to approximately 87.1 trillion KRW by 2027—a tenfold growth over six years. AI has become a core technology reshaping the entire healthcare industry, moving beyond simple auxiliary tools to play a key role in complementing medical professionals and providing better services to patients. AIDOT, after over two years of collaboration with Hanyang University Hospital and Bundang Seoul National University Hospital, has launched the AI medical device "URO dot AI," which accurately identifies the location and size of urinary stones in the kidney, ureter, and bladder.
[Interview: Jae-hak Jung, CEO of H&T Medical]
Q. What is URO dot AI as a solution? Urolithiasis—a condition where stones form in the urinary system—affects 5–10% of the total population at least once in their lives, with around 460,000 patients visiting hospitals in 2022 alone. It is commonly treated using shock wave lithotripsy.
[Interview: Professor Jae-won Oh, Department of Emergency Medicine, Hanyang University]
Q. What prompted the development of URO dot AI?
Q. What are the key strengths of URO dot AI? Insurance reimbursement for urolithiasis treatment depends on the size of the stone. Traditionally, doctors have had to check CT images one by one to see if the stones are under the 4mm threshold, consuming significant time and labor and risking errors. URO dot AI greatly enhances diagnostic accuracy and efficiency. It has also been adopted by the Health Insurance Review and Assessment Service, helping to reduce the national insurance financial burden. Urolithiasis frequently recurs, in part due to family history, with about half of patients experiencing recurrence within a decade. By using URO dot AI for diagnosis and treatment, patients can receive ongoing management and proactive care—helping to reduce additional treatments, related medical costs, patient suffering, and unnecessary government spending.
[Interview: Jaehoon Jung, CEO of AIDOT]
Q. What are AIDOT's future plans for URO dot AI? In this era of medical AI, AIDOT’s URO dot AI is here to lead the way.
Korea Economic TV / 2024.11.04 / Deputy Director Yang Jae-jun
